Background/Aims: Endoscopic resection (ER) procedure has been performed widely to treat gastric neoplasms. Here, we compared the long-term prognosis based on the clinical features of three types of recurred gastric neoplasms after ER, including low-grade dysplasia (LGD), high-grade dysplasia (HGD), and early gastric carcinoma (EGC). Methods: Between 2003 and 2014, subjects who were diagnosed with gastric neoplasm during screening endoscopy were included. The baseline clinicopathologic and tumor recurrence were analyzed. Results: Of the 316 patients enrolled, 170 patients (53.8%) were categorized into the LGD group, 34 patients (10.8%) into the HGD group, and 112 patients (35.4%) into the EGC group. The median follow-up duration was 4.2 years. Among the total, 14 patients experienced a development of metachronous gastric cancer; 4 patients (2.3%) in the LGD group, 3 patients (8.3%) in the HGD group, and 7 patients (6.1%) in the EGC group. Metachronous gastric neoplasm had developed in 17 LGD patients (10.0%), 5 HGD patients (14.7%), and 14 EGC patients (12.5%). There was no significant difference in the incidence of metachronous gastric cancer and neoplasm among the three groups (p=0.15 and p=0.72, respectively). Conclusions: We identified that the incidence rates of gastric neoplasm and cancer after endoscopic treatment were not significantly different between the LGD, HGD, and EGC groups. (Korean J Gastroenterol 2017;70:223-231) 
INTRODUCTION
Stomach cancer is a common malignancy. 1 Detection at an early stage reduces morbidity and improves survival. If there is no metastasis in the lymph nodes, the clinical outcome of early stage gastric cancer is very good, with a 5-year survival rate of 99%. 2 Gastric dysplasia is considered as a premalig-nant lesion, suggesting an increased risk of gastric cancer according to the grade of the dysplasia. [3] [4] [5] [6] Endoscopic resection (ER) has been widely performed to treat certain cases of gastric neoplasm. However, metachronous neoplasm can develop at another site in the stomach because the remnant mucosa may still be affected by precancerous lesions, such as, intestinal metaplasia or gastric 224 정고은 등. 위 신생물의 내시경 절제술 후 재발 양상
The Korean Journal of Gastroenterology atrophy, thus resulting in increased risk for recurrence. 7 In fact, the incidence rate of metachronous or synchronous neoplasm after ER has been reported to be 3.0-20.9%. [8] [9] [10] Previous studies have identified multiple predictors for metachronous neoplasm of the stomach, including Helicobactoer pylori (H. pylori) infection, intestinal metaplasia or gastric atrophy, histologic findings, and grade of dysplasia. 11, 12 Therefore, scheduled endoscopic surveillance is important, especially for high risk patients who have undergone previous ER. LGD in category 3, HGD in category 4, and invasive carcinoma in category 5. 13 Among the 406 cases of ER, 82 cases with less than 12 month of follow-up, 5 cases with additional operation immediately after ER, and 3 cases without ER due to old age were all excluded. This study was approved by the Institutional Review Board of Seoul National University; requirement for written consent was waived.
Endoscopy procedure and follow-up
In almost all cases, ER was performed with the endoscopic submucosal dissection (ESD) technique. Indications for ER were as follows: low-or high-grade dysplasia lesion regardless of tumor size and shape; if the lesion was EGC, histologi-cally-confirmed adenocarcinoma with well or moderate-differentiation, with the depth of invasion confined to mucosa, a lesion less than 2 cm without evidence of distant or lymph node metastasis. Patients with LGD received several treatment modalities, including ESD, endoscopic ablation with argon plasma coagulation, endoscopic mucosal resection, or simple excisional biopsy, and regular surveillance endoscopy with re-biopsy when the size was less than 5 mm, 14 based on the size of the lesion, endoscopist's recommendation, as well as patient preference. After ER for gastric neoplasm, a follow-up endoscopy to detect any mucosal abnormalities was scheduled at 3, 6, and 12 months after ER, and annually thereafter. We defined local recurrence as a lesion found on the ER scar during a surveillance endoscopy. 15 Metachronous' lesion was defined as a lesion that had newly developed more than 1 year after the treatment of the primary lesion.
Clinicopathological evaluations
H. pylori infection was considered positive based on either positive findings on histological examination or a rapid urease test. Mucosal atrophy or intestinal metaplasia was considered to be present based on pathological examination.
Endoscopic severity of gastric atrophy was assessed based on the location of the atrophic border via endoscopy, by distinctive differences in the visible capillary network, height of the gastric mucosa, and color, as reported by Kimura and Takemoto 16 and Liu et al. 17 The extent of EAG was categorized into six grades (C1 to O3) in accordance with the Kimura-Takemoto classification. We grouped the six categories into two types:
antral dominant and corpus dominant types. 16 
Statistics
Chi square test or Student's t-test was performed to com- into the EGC group ( Fig. 1 ).
The baseline characteristics of the three groups are shown in the LGD group and one patient (2.9%) in the HGD group were treated using simple biopsy.
Development of metachronous neoplasm
The overall mean follow-up period was 4.5±2.4 years and ranged from 1.0 to 11.1 years (median 4.2 years). The longest interval between the initial ER and metachronous tumor recurrence was 6.3 years (range 1.1-6.3, median 3.2 years).
During the follow-up period, a total of 14 metachronous gas- cancer was higher in the HGD+EGC group than in the LGD group, with a borderline statistical significance (p=0.06, Fig. 3A) .
However, the incidence rate of the overall gastric neoplasm after ER did not differ between the two groups. (p=0.43 according to the log-rank test, Fig. 3B ). 
DISCUSSION
We aimed to determine the long-term prognosis based on the clinical features of gastric neoplasm after ER with respect to the grade of dysplasia, including LGD, HGD, and EGC in a primary screening center, not in a tertiary referral center. The incidence rates of gastric neoplasm and cancer after endos-copy treatment were not significantly different among the three groups. Consistent with our findings, a recent retrospective study has reported that histological features of gastric neoplasm did not affect the development of metachronous gastric neoplasm. 18 However, in the following points, our study differed from this previous study. First, our study participants were relatively healthy who participated in a health-checkup program, while the previous study was conducted at a referral center in an outpatient clinic. Thus, the generalizability is greater in this study. Second, our study had a relatively long-term follow-up period with a median of 50 months, whereas in the previous study, the median follow-up period was 28 months; therefore, this study shows long-term outcomes with greater precision. Finally, in our study, we showed a comparison among three subgroups based on the primary tumor histology, separating the HGD group from invasive neoplasia, which shows long-term outcomes of three separate subgroups; in the previous study, however, only two subgroups were used.
The incidence rate of metachronous gastric neoplasm was comparable with the previous Korean study, 19 shown that H. pylori eradication after endoscopy treatment did not significantly decrease the incidence of metachronous cancer. 21 Contrastingly, in a randomized controlled study, it was shown that the risk of metachronous carcinoma was reduced in patients with prophylactic H. pylori eradication. 22 In fact, H. pylori eradication has been shown to prevent metachronous gastric cancer after ER; and as a result, it has been incorporated in a recent treatment guideline. 23 However, H. pylori eradication after ER, at the moment, is not covered by the National Health Insurance system in Korea. 24, 25 Despite the removal of gastric neoplasm with the surrounding mucosa by ER, most of the gastric tissues with atrophy or intestinal metaplasia may still remain. Thus, secondary lesions can frequently develop in the preserved stomach mucosa. In this study, the precursor lesions, such as intestinal metaplasia, gastric atrophy, or H. pylori infection, did not differ among the three groups; therefore, there may have been no significant differences in the incidences of metachronous gastric neoplasm. This finding may indicate the concept of field for cancerization, i.e., the exposure of a whole field of tissue to continuous carcinogen resulting the occurrence of cancers in a predisposed filed during multistep process. 26 However, when we combined the two groups together (HGD and EGC), the incidence of metachronous gastric cancer was higher in the combined group than in the LGD group with borderline statistical significance. This suggests that there is a difference in the premalignant potential between LGD and HGD. In fact, a large cohort study with 10 years of follow-up reported that the annual incidence of gastric cancer increased according to the severity of premalignant lesion at the initial diagnosis; 0.6% in mild-to-moderate vs. 6% in severe dysplasia. 27 This confirms our results. In contrast to our results, the cumulative incidence of gastric cancer was not significantly different between the LGD group and the HGD+EGC group in a previous study. 17 This difference may be attributable to the difference in the follow-up periods and discrepancies between the two study populations.
Our study demonstrated the long-term outcomes of subjects with LGD treated with simple excisional biopsy without additional ESD compared with subjects treated with ESD.
There was no significant difference in the incidences of metachronous neoplasm and local recurrence between the simple excisional biopsy-removed group and the ESD-treated group. In this context, these results suggest that 'simple excisional biopsy and follow-up' can be cautiously applied for small LGD in selected settings, such as old age or the presence of comorbidity.
There have been no clinical guidelines for the surveillance interval and duration after endoscopic treatment. In a previous study, patients received follow-up at 2, 6, and 12 months and annually thereafter. 18 In the present study, metachronous gastric cancer developed in a patient with EGC 5.7 years after ER and was retreated using ESD, suggesting the importance of long-term regular surveillance. In one case in the HGD group, advanced gastric cancer was found and treated with gastrectomy with additional chemotherapy due to combined liver metastasis. This indicates that careful surveillance via endoscopy should be encouraged for the dysplasia group as well as for the EGC group with the same levels of attention.
Several factors should be considered when interpreting the results of this study. First, given the retrospective design of the study, the follow-up duration varied widely and there was a problem with the judgement of H. pylori infection status. A prospective study with a large number of participants is warranted to verify our results. Second, we did not evaluate the histologic severity of intestinal metaplasia or gastric atrophy. Further study based on the histological evaluation for the extent of intestinal metaplasia or gastric atrophy is needed to elaborate the results of this study. Third, the sample size may be too small, particularly considering that there were three different categories compared. Fourth, because the specimen obtained using a biopsy material was not representative of the entire lesion, pathological diagnosis based on forcep biopsy may have been inaccurate. 28 Thus, patients with LGD treated with simple excisional biopsy in this study may have confounding effects for the interpretation of long-term follow-up prognosis of ER. Finally, because there is no widely accepted universal interval for a follow-up endoscopy in patients with adenoma, 29 the period of follow-up endoscopy differed between patients with adenoma and those with carcinoma in this study, which may have influenced the quality of the study.
In conclusion, our study has demonstrated the clinical outcome and long-term prognosis of gastric neoplasm treated with ER with respect to the grade of dysplasia. The incidence rates of gastric neoplasm and cancer after endoscopy treatment were not significantly different among the three groups -LGD, HGD, and EGC. Long-term careful endoscopic surveillance should be considered in patients with dysplasia as well as in those with EGC who underwent previous endoscopy treatment.
